RANDOMIZED TRIAL OF CONCURRENT VERSUS SEQUENTIAL DOCETAXEL PLUS BORTEZOMIB ( PS-341) IN PLATINUM-TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): A CALIFORNIA CANCER CONSORTIUM STUDY

被引：0
|
作者：
Lara, P. N.
Longmate, J.
Argiris, A. [1 ]
Gitlitz, B. [2 ]
Mack, P. C. [3 ]
Lau, D.
Koczywas, M.
Leighl, N. B. [4 ]
Gandara, D. R. [5 ]
机构：
[1] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA
[2] Univ So Calif, Los Angeles, CA USA
[3] Univ Calif Davis, Dept Internal Med Hematol Oncol, Sacramento, CA 95817 USA
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[5] Univ Calif Davis, Ctr Canc, Dept Internal Med Hematol Oncol, Sacramento, CA 95817 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [31] Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial
    Lara, PN
    Gandara, DR
    Longmate, J
    Gumerlock, PH
    Martin, DHML
    Edelman, J
    Gandour-Edwards, R
    Mack, PC
    Israel, V
    Raschko, J
    Frankel, P
    Perez, EA
    Lenz, HJ
    Doroshow, JH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (01) : 22 - 28
  • [32] Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients:: A phase II/pharmacodynamic trial.
    Stevenson, JP
    Nho, CW
    Johnson, SW
    Evans, TL
    Algazy, KA
    Gallagher, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 652S - 652S
  • [33] Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
    Rocco, Danilo
    Della Gravara, Luigi
    Malapelle, Umberto
    Troncone, Giancarlo
    Gridelli, Cesare
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S145 - S148
  • [34] Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study
    Davis, NB
    Taber, DA
    Ansari, RH
    Ryan, CW
    George, C
    Vokes, EE
    Vogelzang, NJ
    Stadler, WM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 115 - 119
  • [35] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
  • [36] Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
    Hirata, T
    Kawashita, F
    Ogawa, E
    Masago, K
    Kato, M
    Takada, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 676S - 676S
  • [37] Docetaxel and Exisulind in previously treated non-small cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial
    Weiss, Glen J.
    Vokes, Everett E.
    Bunn, Paul A., Jr.
    Magree, Lyn
    Rusk, Jason
    Albert, Don
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) : 933 - 938
  • [38] Taxanes with platinum compounds in the treatment of non-small cell lung cancer (NSCLC) patients (PTS). Our experience
    Marenich, A
    Gorbounova, V
    Reutova, E
    Kozlov, D
    Breder, V
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 253 - 256
  • [39] Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study
    Zatloukal, P
    Petruzelka, L
    Zemanova, M
    Havel, L
    Janku, F
    Judas, L
    Kubik, A
    Krepela, E
    Fiala, P
    Pecen, L
    LUNG CANCER, 2004, 46 (01) : 87 - 98
  • [40] Weekly administration of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC).
    Sun, Y
    Li, J
    Wu, Y
    Li, L
    Gu, L
    Zhang, L
    Wang, J
    Zhang, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
12345